Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer.

Authors

Boon Hao Hong, Adeniyi A Olabumuyi, Shuang G Zhao, Purvish Trivedi, Ryan Putney, Esther Katende, Amparo Serna, Riley Smith, Jasreman Dhillon, Jong Y Park, Rodrigo Pessoa, Michael Poch, Daniel Grass, Julio Pow-Sang, Alexander Hakansson, Yang Liu, Elai Davicioni, Yi Ren, Siyi Tang, Danielle Croucher, Huei-Chung Huang, S Laura Chang, Mary Feng, Rikiya Yamashita, Enya H W Ong, Kae Jack Tay, Kah Min Tan, Jeffrey K L Tuan, Michael L C Wang, Li Yan Khor, Olivia G Jordan, Jinhee Chang, Claudia Datnow-Martinez, Xiaolei Shi, Amol Shetty, Zaker H Rana, Jason K Molitoris, Mark V Mishra, Young Kwok, Yang Song, Matthew Ramotar, Alejandro Berlin, Ozan Guler, Cem Onal, Loig Vaugier, Audrey Blanc-Lapierre, Stéphane Supiot, Carole Mercier, Piet Dirix, Piet Ost, Ryan J Park, Chad Tang, Michael K Rooney, Shalin Shah, Lauren Mayo, Seungtaek Choi, Steven J Frank, Comron Hassanzadeh, Karen Hoffman, Sean McGuire, Osama Mohamad, Henry Mok, Quynh-Nhu Nguyen, Krishnan R Patel, Theodore DeWeese, Ana P Kiess, Daniel Song, Scott E Delacroix, Daniel E Spratt, Paul L Nguyen, Matthew Deek, Phuoc T Tran, Philip Sutera, Melvin L K Chua, Kosj Yamoah

Published in

Clinical cancer research : an official journal of the American Association for Cancer Research. Oct 08, 2026. Epub Oct 08, 2026.

Abstract

The Decipher Prostate Genomic Classifier (GC) and ArteraAI Multimodal Artificial Intelligence (MMAI) platform are widely used prognostic tools for localized prostate cancer (PCa), yet no direct comparison has been performed within the same patient cohort.
We sought to evaluate the concordance and prognostic value of GC and MMAI across multi-institutional cohorts totaling 688 patients with localized and oligometastatic PCa. These included populations enriched for African American and East Asian patients. GC and MMAI scores were stratified into risk groups based on specimen type (biopsy or radical prostatectomy (RP)). The primary endpoint was distant metastasis-free survival (DMFS), measured from diagnosis to last follow-up or event.
GC and MMAI scores were significantly correlated across multiple cohorts. In Moffitt RP, biopsy, and NCCS cohorts, both MMAI and GC were prognostic alone and after adjusting for clinical variables. Multivariable analysis including both biomarkers and clinical variables showed that MMAI was significant even accounting for GC in Moffitt RP, and borderline in Moffitt biopsy. Analysis of concordant/discordant cases showed that patients who were high-risk for both GC and MMAI did qualitatively worse. In pathway analysis, concordance with GC and MMAI was high for Moffitt RP and oligometastatic patients. Across both biopsy cohorts, while most biological pathways were concordant, there were consistent discordant signaling, metabolic, and DNA repair pathways.
In the first direct patient-level comparison of GC and MMAI in PCa, these biomarkers were found to demonstrate moderate correlation, and both biomarkers demonstrated prognostic value across diverse populations and disease states.

PMID:
42848319
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.